Format

Send to

Choose Destination
Pharmacogenomics. 2018 Apr;19(5):383-392. doi: 10.2217/pgs-2017-0162. Epub 2018 Mar 8.

Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.

Xiao W1, Guo JP1, Li C1, Ye H1, Wei W2, Zou Y3, Dai L4, Li Z5, Zhang M6, Li X7, Cai X8, Zhao J9, Wang Y10, Tao Y11, Liu D12, Li Y13, Wu M14, Sun E15, Wu L16, Luo L17, Mu R1, Li Z1.

Author information

1
Department of Rheumatology & Immunology, People's Hospital, Peking University, Beijing, PR China.
2
Department of Rheumatology & Immunology, Tianjin Medical University General Hospital, Tianjin, PR China.
3
Department of Rheumatology & Immunology, Wuxi People's Hospital, Wuxi, Jiangsu, PR China.
4
Department of Rheumatology & Immunology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
5
Department of Rheumatology & Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, PR China.
6
Department of Rheumatology & Immunology, The First Affiliated Hospital with Nanjing, Nanjing, Jiangsu, PR China.
7
Department of Rheumatology & Immunology, Anhui Provincial Hospital, Hefei, Anhui, PR China.
8
Department of Rheumatology & Immunology, Guangzhou First People's Hospital, Guangzhou, Guangdong, PR China.
9
Department of Rheumatology & Immunology, Jining No.1 People's Hospital, Jining, Shandong, PR China.
10
Department of Rheumatology & Immunology, Jiangxi Provincial People's Hospital, Xinyu, Jiangxi, PR China.
11
Department of Rheumatology & Immunology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China.
12
Department of Rheumatology & Immunology, Shenzhen People's Hospital, Shenzhen, Guangzhou, PR China.
13
Department of Rheumatology & Immunology, Zhejiang Provincial People's Hospital, Huzhou, Zhejiang, PR China.
14
Department of Rheumatology & Immunology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, PR China.
15
Department of Rheumatology & Immunology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, PR China.
16
Department of Rheumatology & Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang Uygur Autonomous Region, PR China.
17
Department of Rheumatology & Immunology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, PR China.

Abstract

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety.

AIM:

The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA.

MATERIALS & METHODS:

Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers.

CONCLUSION:

Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.

KEYWORDS:

efficacy; genetic predictors; iguratimod; rheumatoid arthritis; toxicity

PMID:
29517409
DOI:
10.2217/pgs-2017-0162
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center